Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone

Journal of Psychopharmacology

Volumn 25, Issue 6, 2011, Pages 734-743

  Frankle, W Gordon ^a   Lombardo, Ilise ^b   Kegeles, Lawrence S ^a   Slifstein, Mark ^a   Martin, John H ^a   Huang, Yiyun ^a   Hwang, Dah Ren ^a   Reich, Elisa ^a   Cangiano, Claudine ^a   Gil, Roberto ^a   Abi Dargham, Anissa ^a   Laruelle, Marc ^a,c,d  

^a New York State Psychiatric Institute ^*  (United States)

^b PFIZER INC   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

5 HT1A receptor; 11C WAY 100635; PET; schizophrenia; ziprasidone

Indexed keywords

CARBON 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG RESPONSE; FEMALE; HUMAN; IN VIVO STUDY; MALE; NEGATIVE SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CARBON RADIOISOTOPES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; PYRIDINES; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1A; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; THIAZOLES;

EID: 79960525590     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110388329     Document Type: Article

References (71)

1. Abi-Dargham A, Laruelle M, Seibyl J, et al. SPECT measurement of benzodiazepine receptors in human brain with [123-I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med. 1994 ; 35: 228-238 (Pubitemid 24048309)
2. Abi-Dargham A, Martinez D, Mawlawi O, et al. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab. 2000 ; 20: 225-243 (Pubitemid 30108440)
3. Andree B, Hedman A, Thorberg SO, Nilsson D, Halldin C, Farde L. Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain. Psychopharmacology (Berl). 2003 ; 167: 37-45 (Pubitemid 36535290)
4. Andree B, Thorberg SO, Halldin C, Farde L. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl). 1999 ; 144: 303-305 (Pubitemid 29307285)
5. Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. J Psychopharmacol. 2001 ; 15: 37-46 (Pubitemid 32242102)
6. Bantick RA, Montgomery AJ, Bench CJ, et al. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol. 2004a ; 18: 346-354 (Pubitemid 39386285)
7. Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, Grasby PM. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology. 2004b ; 29: 847-859 (Pubitemid 38528764)
8. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999 ; 38: 1083-1152 (Pubitemid 29292403)
9. Brody D, Adler LA, Kim T, Angrist B, Rotrosen J. Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacol. 1990 ; 10: 68-69 (Pubitemid 20096227)
10. Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 1996 ; 15: 442-455 (Pubitemid 26389868)
11. Burnet PWJ, Eastwood SL, Harrison PJ. [H-3]WAY-100635 for 5-HT1A receptor autoradiography in human brain: A comparison with [H-3]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int. 1997 ; 30: 565-574 (Pubitemid 27187227)
12. Duvernoy H The Human Brain. Surface, Three-dimensional Sectional Anatomy and MRI. New York: Springer-Verlag ; 1991 :
13. Farde L, Andree B, Ginovart N, Halldin C, Thorberg S. PET-Determination of robalzotan (NAD-299) induced 5-HT(1A) receptor occupancy in the monkey brain. Neuropsychopharmacology. 2000 ; 22: 422-429 (Pubitemid 30105770)
14. Farde L, Ginovart N, Ito H, et al. PET-characterization of [carbonyl-C-11]WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacology. 1997 ; 133: 196-202 (Pubitemid 27404751)
15. Frankle WG, Lombardo I, Kegeles LS, et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [(11)C]WAY 100635. Psychopharmacology (Berl). 2006 ; 189: 155-164 (Pubitemid 44691538)
16. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol. 1991 ; 11: 193-197
17. Gozlan H, Thibault S, Laporte AM, Lima L, Hamon M. The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. Eur J Pharmacol. 1995 ; 288: 173-186
18. Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study. Biol Psychiatry. 1997 ; 42: 529-545 (Pubitemid 27425471)
19. Hall H, Lundkvist C, Halldin C, et al. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res. 1997 ; 745: 96-108 (Pubitemid 27055749)
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psych. 1960 ; 23: 56-62
21. Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 1991 ; 48: 355-363
22. Hoyer D, Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res. 1986 ; 376: 85-96 (Pubitemid 16046019)
23. Hwang DR, Simpson N, Montoya J, Mann JJ, Laruelle M. An improved one-pot procedure for the preparation of [11C-carbonyl]WAY 100635. Nucl Med Biol. 1999 ; 26: 815-819 (Pubitemid 29509807)
24. Innis R, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cerebral Blood Flow Metab. 2007 ; 27: 1533-1539 (Pubitemid 47301451)
25. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol. 2002 ; 441: 137-140 (Pubitemid 34626163)
26. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 1993 ; 8: 315-336 (Pubitemid 23162958)
27. Kates WR, Abrams MT, Kaufmann WE, Breiter SN, Reiss AL. Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome. Psychiat Res Neuroimag. 1997 ; 75: 31-48 (Pubitemid 27372180)
28. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull. 1987 ; 13: 261-276 (Pubitemid 18039085)
29. Killiany RJ, Moss MB, Nicholson T, Jolez F, Sandor T. An interactive procedure for extracting features of the brain from magnetic resonance images: the lobes. Human Brain Mapping. 1997 ; 5: 355-363 (Pubitemid 27479397)
30. Kumar JS, Prabhakaran J, Majo VJ, et al. Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2- methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine -3,5(2H,4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging. 2007 ; 34: 1050-1060 (Pubitemid 46919551)
31. Lacerda AL, Hardan AY, Yorbik O, Vemulapalli M, Prasad KM, Keshavan MS. Morphology of the orbitofrontal cortex in first-episode schizophrenia: relationship with negative symptomatology. Prog Neuropsychopharmacol Biol Psychiatry. 2007 ; 31: 510-516 (Pubitemid 46209451)
32. Mah L, Arnold MC, Grafman J. Impairment of social perception associated with lesions of the prefrontal cortex. Am J Psychiatry. 2004 ; 161: 1247-1255 (Pubitemid 38859175)
33. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007 ; 164: 1411-1417 (Pubitemid 47461142)
34. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004 ; 161: 818-825 (Pubitemid 38625334)
35. Martinez D, Hwang D, Mawlawi O, et al. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol. A dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology. 2001a ; 24: 209-229 (Pubitemid 32146193)
36. Martinez D, Hwang D, Mawlawi O, et al. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology. 2001b ; 24 (3). 209-229 (Pubitemid 32146193)
37. Mawlawi OM, Weiss R, Shinn A, Pidcock J, Slifstien M, Laruelle M. Performance characteristics of a head immobilization device for PET imaging. J Nucl Med. 1999 ; 40: 281P - 281P
38. Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?. Behav Brain Res. 2008 ; 195: 98-102
39. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984 ; 15: 217-227 (Pubitemid 14164735)
40. Mongeau R, Welner SA, Quirion R, Suranyi-Cadotte BE. Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus. Brain Res. 1992 ; 590: 229-238
41. Nakayama T, Suhara T, Okubo Y, et al. In vivo drug action of tandospirone at 5-HT1A receptor examined using positron emission tomography and neuroendocrine response. Psychopharmacology (Berl). 2002 ; 165: 37-42 (Pubitemid 36044729)
42. Newman-Tancredi A, Assie MB, Leduc N, Ormiere AM, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol. 2005 ; 8: 341-356 (Pubitemid 41002489)
43. Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 ; 355: 245-256 (Pubitemid 28404707)
44. Osman S, Lundkvist C, Pike VW, et al. Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behavior of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl Med Biol. 1996 ; 23: 627-634 (Pubitemid 26295578)
45. Pani L, Gessa GL, Carboni S, Portas CM, Rossetti ZL. Brain dialysis and dopamine: does the extracellular concentration of dopamine reflect synaptic release?. Eur J Pharmacol. 1990 ; 180: 85-90 (Pubitemid 20140993)
46. Parsey RV, Slifstein M, Hwang DR, et al. Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions. J Cereb Blood Flow Metab. 2000 ; 20: 1111-1133 (Pubitemid 30445623)
47. Price JL. Prefrontal cortical networks related to visceral function and mood. Ann N Y Acad Sci. 1999 ; 877: 383-396 (Pubitemid 29351868)
48. Rabiner EA, Gunn RN, Wilkins MR, et al. Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl Med Biol. 2000 ; 27: 509-513 (Pubitemid 30658155)
49. Rabiner EA, Gunn RN, Wilkins MR, Sedman E, Grasby PM. Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol. 2002a ; 16: 195-199 (Pubitemid 34983072)
50. Rabiner EA, Messa C, Sargent PA, et al. A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage. 2002b ; 15: 620-632 (Pubitemid 34852530)
51. Rabiner EA, Wilkins MR, Turkheimer F, et al. 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4- benzdioxyn-5-yl)-1-piperazinyl]butyl]-1, 2-benzisothiazol-3-(2H)-one-1,1- dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N- (2-py ridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther. 2002c ; 301: 1144-1150 (Pubitemid 34600965)
52. Raje S, Patat AA, Parks V, et al. A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease. Clin Pharmacol Ther. 2008 ; 83: 86-96
53. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000 ; 48: 229-237 (Pubitemid 30618995)
54. Rollema H, Lu Y, Schmidt AW, Zorn SH. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol. 1997 ; 338: R3 - R5
55. Simpson MD, Lubman DI, Slater P, Deakin JF. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry. 1996 ; 39: 919-928
56. Sirota P, Epstein B, Benatov R, Sousnostzky M, Kindler S. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J Clin Psychopharmacol. 2001 ; 21: 454-455 (Pubitemid 32673037)
57. Slater P, Doyle CA, Deakin JF. Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates. J Neural Transm. 1998 ; 105: 305-315 (Pubitemid 28243238)
58. Sovner R, Parnell-Sovner N. Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacol. 1989 ; 9: 61-62
59. Spitzer R, Williams J, Gibbon M, First M. The Structured Clinical interview for DSM-III-R: 1. History, rationale and description. Arch Gen Psychiatry. 1992 ; 49: 624-629
60. Sumiyoshi T, Higuchi Y, Matsui M, et al. Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007a ; 31: 965-967 (Pubitemid 46660309)
61. Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001a ; 158: 1722-1725 (Pubitemid 32923670)
62. Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry. 2001b ; 49: 861-868 (Pubitemid 32436390)
63. Sumiyoshi T, Matsui M, Yamashita I, et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol. 2000 ; 20: 386-388 (Pubitemid 30318373)
64. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007b ; 95: 158-168 (Pubitemid 47313647)
65. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 1996 ; 708: 209-214
66. Talairach J, Tournoux P Co-planar Stereotactic Atlas of the Human Brain. Three-dimensional Proportional System: An Approach of Cerebral Imaging. New York: Theime Medical Publisher ; 1988 :
67. Tauscher J, Kapur S, Verhoeff NP, et al. Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry. 2002 ; 59: 514-520 (Pubitemid 34602933)
68. Vernaleken I, Fellows C, Janouschek H, et al. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol. 2008 ; 28: 608-617
69. Wadenberg ML. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev. 1996 ; 20: 325-339
70. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comp Assist Tomogr. 1992 ; 16: 620-633
71. Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry. 2004 ; 55: 439-444 (Pubitemid 38338529)